Form 4: Soleno Therapeutics CEO Completes Merger-Related Transactions

Anish Bhatnagar, CEO of Soleno Therapeutics, reports changes in beneficial ownership following the company's merger with Neocrine Biosciences.

Summary

• Anish Bhatnagar, Chief Executive Officer and Director of Soleno Therapeutics Inc. (SLNO), has filed a Form 4 detailing transactions related to the company's merger.
• The merger, effective May 18, 2026, involved Soleno Therapeutics, Neocrine Biosciences, Inc. (Parent), and Sigma Merger Sub, Inc. (Merger Sub).
• In connection with the merger, each outstanding restricted stock unit (RSU) was cancelled and converted into the right to receive $53.00 in cash.
• Similarly, each outstanding share of Soleno Therapeutics' Common Stock was converted into the right to receive $53.00 in cash.
• Employee stock options were also cancelled in exchange for a cash payment equal to the difference between the merger consideration ($53.00) and the per-share exercise price, multiplied by the number of shares covered by the option.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports on the completion of a merger and the subsequent conversion of equity into cash, which is a standard outcome for such transactions.

Positives

• The merger was successfully completed, providing a cash payout of $53.00 per share for common stock and RSUs.
• Executive leadership, including the CEO, participated in the merger-related transactions, indicating alignment with the transaction's outcome.

Negatives

• All outstanding common stock, RSUs, and employee stock options were cancelled as part of the merger, eliminating direct equity ownership in the surviving entity for these instruments.

Risks

• The filing does not explicitly mention any ongoing risks or future challenges, as it primarily reports on completed merger transactions.

Future Outlook

The filing is a report of past transactions related to a completed merger and does not contain forward-looking statements or guidance.

Management Comments

• The filing details the conversion of RSUs, common stock, and stock options into cash payments as part of the merger agreement.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting changes in beneficial ownership by insiders, particularly during significant corporate events like mergers and acquisitions. This filing confirms the completion of the merger between Soleno Therapeutics and Neocrine Biosciences, as outlined in their merger agreement.

Stakeholder Impact

• Shareholders: Received $53.00 in cash per share for their common stock.
• RSU Holders: Received $53.00 in cash for each vested and unvested RSU.
• Option Holders: Received cash payments based on the difference between the merger consideration and their option's exercise price.
• Employees: May experience changes in roles or reporting structures as Soleno Therapeutics becomes a subsidiary of Neocrine Biosciences.

Next Steps

• Soleno Therapeutics will now operate as a wholly owned subsidiary of Neocrine Biosciences, Inc.

Key Dates

Keywords

Form 4, SEC Filing, Soleno Therapeutics, SLNO, Merger, Anish Bhatnagar, CEO, Beneficial Ownership, Restricted Stock Units, Stock Options, Neocrine Biosciences